Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.09 USD

28.09
46,845,401

-0.21 (-0.74%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $28.11 +0.02 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (58 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Will Pfizer (PFE) Beat Expectations This Earnings Season?

Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like Vyndaqel/Vyndamax are likely to have contributed to Pfizer's (PFE) sales growth in Q1.

Seagen's (SGEN) Q1 Earnings and Revenues Miss Expectations

Seagen (SGEN) reports worse-than-expected results in the first quarter of 2023, missing both earnings and sales estimates.

Bristol-Myers (BMY) Q1 Earnings Beat, Revlimid Generics Hurt Sales

Bristol-Myers' (BMY) first-quarter 2023 earnings top estimates, while sales missed the same and declined year over year due to generic erosion for the oncology drug Revlimid.

Merck (MRK) Surpasses Q1 Earnings and Revenue Estimates

Merck (MRK) delivered earnings and revenue surprises of 4.48% and 4.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Pfizer (PFE) closed at $39.91, marking a -0.75% move from the previous day.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Here's Why You Should Add Allogene (ALLO) Stock to Your Portfolio

Allogene Therapeutics (ALLO), a top-ranked stock, is currently focused on developing allogenic CAR T therapies for treating cancer.

The Zacks Analyst Blog Highlights Pfizer, Accenture, Wells Fargo, Starbucks and Chubb

Pfizer, Accenture, Wells Fargo, Starbucks and Chubb are part of the Zacks top Analyst Blog.

Sundeep Ganoria  headshot

FDA Gives Nod for Using Bivalent Jab for All COVID Vaccinations

To simplify the COVID-19 vaccination schedule for all individuals, the FDA authorizes using bivalent COVID-19 vaccines for all doses administered to individuals aged six years and older.

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

Pfizer (PFE) closed the most recent trading day at $40.55, moving -1.53% from the previous trading session.

Sheraz Mian headshot

Finance Sector Scorecard and Analyst Reports for Pfizer, Accenture & Wells Fargo

Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), Accenture plc (ACN) and Wells Fargo & Company (WFC).

Vaxcyte (PCVX) Up on Pneumococcal Conjugate Vaccine Data

Vaxcyte (PCVX) announces positive results from the mid-stage study of its 24-Valent pneumococcal conjugate vaccine candidate, VAX-24, in adults aged 65 and older.

FDA Expands AbbVie's (ABBV) Qulipta Label in Chronic Migraine

Following FDA's label-expansion approval, AbbVie's (ABBV) Qulipta is the first and the only oral CGRP receptor antagonist approved to prevent episodic and chronic migraines.

Why Pfizer (PFE) is Poised to Beat Earnings Estimates Again

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Johnson & Johnson (JNJ) Q1 Earnings and Revenues Top Estimates

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 6.77% and 5.01%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Pfizer (PFE) Stock Moves 0.14%: What You Should Know

Pfizer (PFE) closed the most recent trading day at $41.79, moving +0.14% from the previous trading session.

AstraZeneca (AZN), Sanofi Simply RSV Antibody Agreement Terms

AstraZeneca (AZN) and Sanofi (SNY) revise the contractual terms of the agreement for Beyfortus. Sanofi will have full commercial control of Beyfortus in the United States.

Yashwardhan Jain headshot

3 Sector ETFs to Play as Recession Fears Are on the Rise

With recession fears on the rise, look into some sectors that can shield from market volatility.

The Zacks Analyst Blog Highlights J&J, AstraZeneca, Merck, Seagen and Pfizer

J&J, AstraZeneca, Merck, Seagen and Pfizer are part of the Zacks Top Analyst Blog.

Zacks Investment Ideas feature highlights: Nvidia, United Healthcare, Merck, Pfizer and Intuitive Surgical

Nvidia, United Healthcare, Merck, Pfizer and Intuitive Surgical are part of the Zacks Investment Ideas article.

Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Smart Beta ETF report for PJP

Kinjel Shah headshot

Pharma Stock Roundup: J&J's $8.9B Offer for Talc Litigation Settlement & Other Updates

J&J (JNJ) offers a $8.9 billion settlement to resolve its talc lawsuits. FDA approves Merck's (MRK) Keytruda plus Seagen's Padcev for a bladder cancer indication.